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RNA molecules have key roles in many essential biological 
processes, including protein synthesis, transcriptional regu- 
lation, mRNA splicing and retroviral replication. The struc- 
tural diversity of RNA, together with the lack of known 
RNA repair mechanisms, make RNA a challenging and 
important target for therapeutic intervention [I]. Our 
understanding of the modes by which RNA is recognized 
by ligands is far from being comprehensive, although sig- 
nificant advances have been made [Z]. In order to target 
pivotal bacterial or viral RNA sites, one would like to be 
able to identify well-defined binding motifs that will facili- 
tate the design and synthesis of new binders [3]. 
The functional diversity of RNA is based on the complex 
three-dimensional folds it can adopt. This structural 
sophistication leads to the formation of potential binding 
pockets for ions, ligands and proteins. The interaction of 
ligands with RNA is likely to be ‘shape-specific’ rather 
than sequence-specific. This adds to the complexity of the 
problem of designing effecters targeted at RNA, as the 
prediction of both the folded structure and putative 
binding sites for certain ligands is not at all trivial [4,5]. 
The discovery that aminoglycoside antibiotics bind to 
diverse RNA molecules such as ribosomal RNA [6], group 
I introns [7,8] and the hammerhead [9] and hepatitis delta 
virus [lo] ribozymes, as well as the finding that antibiotics 
block the binding of the Rev protein [l l] and Tat peptide 
[ 121 to their viral RNA targets, have attracted considerable 
interest [13,14]. Although at first glance it appears that 
these antibiotics interact with seemingly unrelated RNA 
molecules, they are likely to recognize similar structural 
motifs within RNA folds. Our understanding of aminogly- 
coside binding to RNA has advanced considerably 
recently. In o&-o selection studies have identified various 
RNA sequences that bind aminoglycosides with high 
affinity [15-171, although these aptamers might not share 
the same binding characteristics as naturally occurring 
RNAs. Structures solved using nuclear magnetic reso- 
nance (NMR) have begun to reveal details of RNA recog- 
nition at the molecular level [l&19], and a number of 
other approaches have focused on issues of specificity in 
RNA-aminoglycoside binding [ZO-231. 
The purpose of this article is to combine recent experi- 
mental and theoretical studies that have focused on the 
interactions between aminoglycoside antibiotics and the 
hammerhead ribozyme. We view this system as a para- 
digm that allows one to explore the interaction between 
small organic molecules and a catalytically active RNA. 
Although this system might not necessarily reflect the sit- 
uation in vivo, it encompasses several valuable features: 
the hammerhead ribozyme is a well-studied catalytic RNA 
that has been kinetically characterized [24], and it has 
been shown to be efficiently inhibited by aminoglycoside 
antibiotics [9]; competition with magnesium ions has been 
suggested to be relevant to aminoglycoside binding [‘25]; 
and, importantly, the crystal structures of two hammer- 
head ribozymes have been reported [26-281. As we illus- 
trate in this article, by utilizing synthetic chemistry, 
biochemical assays, molecular modeling and molecular- 
dynamics simulations, important elements pertinent to 
the hammerhead-aminoglycoside binding can now be 
deciphered. A novel recognition model that sheds light on 
antibiotic-RNA binding is discussed and its potential gen- 
erality and use in future drug design is evaluated. 
Aminoglycoside antibiotics inhibit the hammerhead 
ribozyme 
Figure 1 shows the structure of two representative fami- 
lies of aminoglycoside antibiotics. All members contain 
the highlighted Z-deoxystreptamine (Z-DOS) core. Glyco- 
sylation of the 4- and 6-hydroxyl groups with various 
aminosugars yields the kanamycin family, whereas glyco- 
sylation of the 4- and 5hydroxyl groups of Z-DOS charac- 
terizes the neomycin family. The presence of a number of 
amino groups with a range of pKa values (5.7-8.8) makes 
these natural products highly charged at physiological pH 
[29-311. The polycationic pseudo-oligosaccharide antibi- 
otics are best known for their ability to interfere with ribo- 
somal function in prokaryotes through binding to’ the 
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decoding region on ribosomal RNA [6,32]; this disrupts 
bacterial protein biosynthesis and confers strong bacterici- 
dal properties onto the antibiotics. Recent studies have 
demonstrated that aminoglycoside antibiotics also bind to 
the HIV-l Rev response element (RRE) [ 111 and the trans 
activating response element (TAR) [12], as well as to 
numerous ribozymes [7-lo]. 
Stage et al. [9] have investigated aminoglycoside antibi- 
otics as inhibitors of the hammerhead ribozymes 
(Figure Z), and found neomycin B to be a potent inhibitor 
of the cleavage reaction with a K, of 13.5 PM. The data 
indicated that the antibiotics interacted preferentially with 
the enzyme-substrate complex. This interaction has been 
suggested to reduce the cleavage rate by stabilizing the 
ground state of the complex and destabilizing the transi- 
tion state leading to the phosphodiester cleavage. Com- 
paring the inhibitory activity of various aminoglycosides 
implied that the number of ammonium groups on the 
antibiotics is important for RNA binding. By studying the 
inhibition as a function of pH and Mg2+ concentration, it 
was concluded that the positively charged neomycin 
inhibits the hammerhead ribozyme by displacing critical 
Mgz+ ions under physiologically relevant conditions [2.5]. 
Binding affinities of modified aminoglycosides correlate 
with the number of positive charges 
Further support for the role of electrostatic interactions in 
RNA-aminoglycoside binding has been obtained by inves- 
tigating synthetic ‘amino-aminoglycosides’ [33]. We have 
replaced the primary CH,OH group in natural aminoglyco- 
sides with a highly basic CH,NH, group (Figure 3). These 
‘amino-aminoglycosides’ have enhanced binding affinity 
for the hammerhead ribozyme when compared to the 
parent natural products. Kanamycin A, a poor RNA-binder 
that contains four amino groups, is converted into a reason- 
ably strong inhibitor upon the incorporation of an addi- 
tional amino group. Thus, 6”-amino-6”-deoxykanamycin A 
is as effective as kanamycin B, a natural product containing 
five amino groups. Similarly, modifying a stronger binder 
such as tobramycin further enhances its affinity for the 
hammerhead ribozyme: 6”-amino-6”-deoxytobramycin is 
approximately fivefold more effective than the parent 
tobramycin as a ribozyme inhibitor. Even the binding affin- 
ity of neomycin B, one of the strongest RNA binders, can 
be further enhanced by converting it to 5”-amino-5”- 
deoxyneomycin B. These results suggest that increasing 
the overall charge of a ligand is an important mechanism 
for increasing RNA affinity. 
Binding affinities correlate with the basicity of the 
ammonium groups 
Tobramycin inhibits the hammerhead ribozyme more 
effectively than kanamycin B although both compounds 
contain the same number of amino groups (five), and this 
trend is seen in other RNA systems that have been 
explored [7,8,11]. The only difference between the two 
antibiotics is an additional hydroxyl group at the 3’ posi- 
tion in kanamycin B. How can the presence of a hydroxyl 
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Secondary structure of the hammerhead ribozyme 16 (HHl6) showing 
the ‘enzyme’ El 6 and the ‘substrate’ S16. The arrowhead indicates the 
cleavage site. 
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Figure 3 
Parent aminoglycosides and their synthetic 
‘amino-aminoglycosides’ derivatives. The 
relative ribozyme cleavage rate in the presence 
of the antibiotics (100 PM for kanamycins, 
10 PM for tobramycins and neomycins) is 
normalized to the ribozyme cleavage rate in the 
absence of antibiotics [33I. 
Cleavage 
Ri R2 R3 rate 
Kanamycin A OH OH OH 0.77 
g’-Amino-6’-deoxykanamycin A OH OH NH, 0.24 
Tobramycin NH2 H OH 0.68 
6’-Amino-6’-deoxytobramycin NH* H NH> 0.15 
Neomycin B OH 0.24 
5’-Amino-5’-deoxyneomycin B NH2 0.04 
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group impede RNA binding? We studied a series of deoxy- 
genated tobramycin derivatives in which the hydroxyl 
groups had been systematically removed while all other 
functional groups were kept intact [34]. The most potent 
ribozyme inhibitors are the deoxygenated derivatives 
lacking the 2”-, 4”- and 4’-hydroxyl groups (Figure 4). In 
contrast, removal of the primary 6”-hydroxyl group results 
in a poorer RNA binder than the parent tobramycin. The 
results indicate that when a hydroxyl group proximal to an 
amine group is removed, higher inhibitory activity is 
observed; these observations were attributed to the 
increased basicity of an amino group in the absence of a 
neighboring hydroxyl group, similar to the trend observed 
with aliphatic amines (HOCH,CH,NH,+, pK,=9.5; 
CH,CH,NH,+, pK,= 10.7) [35]. Thus, the deoxygenated 
aminoglycoside derivatives might have a higher positive 
charge density at a given pH than their parent natural 
product. These observations support the critical role of 
electrostatic interactions in RNA binding, and suggest that 
altering the pK, of amino groups is an important mechanism 
for modulating the affinity of synthetic ligands for RNA. 
In summary, the studies with synthetically modified 
aminoglycosides have revealed two consistent trends in 
aminoglycoside inhibition of the hammerhead ribozyme. 
Firstly, increasing the number of positive charges on the 
antibiotics increases their binding affinities. Secondly, a 
higher basicity of the amino groups (leading to a higher 
charge density at neutral pH) enhances further the affini- 
ties for aminoglycoside binding to the RNA. We will now 
discuss how these findings can be incorporated into a 
model developed independently for the recognition of the 
hammerhead RNA by aminoglycosides. 
How do aminoglycosides bind to the hammerhead 
ribozyme? 
Aminoglycosides contain several inter-ring glycosyl bonds 
about which rotation is allowed, albeit in a sterically hin- 
dered fashion. Figure 5a shows the energy map for rota- 
tions about the @ and ‘P torsion angles between rings A 
and B of neamine, the invariant unit of most active amino- 
glycoside antibiotics. The map displays two main minima, 
a broad one (around -150”/-150”) and a sharp one (around 
+75”/-150”), connected by a shallow valley that marks the 
path of interconversion between the principal conformers. 
Thus, variations in those two angles, along with additional 
steric interactions of further ligands connected to the 
neamine moiety, lead to numerous conformers of amino- 
glycosides [36]. The four inter-ammonium distances 
observed in the accessible solution conformers of amino- 
glycosides can be parsed into two main sets: two are intra- 
ring and rather invariant, whereas the other two are 
inter-ring and rather variable (Figure 5b). 
Crystal structure analyses have revealed a number of mag- 
nesium ions located within the cavity formed by the deep 
grooves of stems I and II (which face each other) in the 
three-dimensional fold of the hammerhead ribozyme 
[27,28]. The bandwidth of inter-Mg2+ distances in solution 
conformations of the hammerhead RNA was explored 
Figure 4 
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Parent aminoglycosides and their synthetic deoxytobramycin 
derivatives. The relative ribozyme cleavage rate in the presence of 
100 PM antibiotics is normalized to the ribozyme cleavage rate in the 
absence of antibiotics [341. 
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Congruent sets of inter-ionic distances between the solution 
conformers of aminoglycosides and the hammerhead ribozyme. 
(a) Adiabatic map of the two torsion angles connecting rings A and B 
of the neamine core common to all aminoglycosides. (b) Intramolecular 
distances between ammonium groups observed in solution conformers 
of various aminoglycosides 1361. (c) Inter-ionic distances between 
magnesium ions bound in the cavity of the hammerhead ribozyme 
[28,36,37]. The cleavage site is marked in yellow. 
using molecular-dynamics simulations [37]. These calcula- 
tions revealed a striking congruence between the inter- 
ionic Mgz+-Mg2+ dist antes in the free ribozyme (Figure SC) 
and the intramolecular distances between the positively 
charged ammonium groups in solvated aminoglycosides 
(Figure 5b) [36]. It was suggested that the covalently 
linked array of ammonium groups in the antibiotics is 
capable of displacing three or four magnesium ions in the 
hammerhead ribozyme by complementing the negative 
electrostatic potential created by the RNA fold [36]. 
Indeed, many solution conformers of different aminoglyco- 
sides could be successfully docked with the hammerhead 
fold in such a way that ammonium groups of aminoglyco- 
sides occupy sites of Mg2+ ions in the RNA crystal structure 
(Figure 6) [36]. This hypothesis has been assessed using 
molecular-dynamics simulations of complexes of the ham- 
merhead RNA and aminoglycoside antibiotics Analysis of 
the molecular-dynamics trajectories of the drug-RNA com- 
plexes revealed that the stable interactions formed 
between the ammonium groups of the aminoglycosides and 
the RNA are almost identical (down to an atomic level) to 
the interactions observed for Mg2+ in the hammerhead 
crystal structure (Figure 6) [36]. 
Water-mediated contacts contribute to three-dimensional 
electrostatic complementarity 
Water molecules play an important role in mediating inter- 
actions between the RNA and both magnesium ions and 
aminoglycosides (Figure 6b,c). The ability of water mole- 
cules to rearrange at the interface between the bound 
species and the RNA provides the maximum number of 
hydrogen-bonding contacts at an optimal distance and ori- 
entation. The fact that several solution conformations of 
aminoglycosides could be docked with the hammerhead 
RNA (and not just one) shows that the relative arrange- 
ment of ammonium groups in the drugs provides a set of 
spatially oriented positive charges that could complement 
in various ways the field created by the electronegative 
cavity of the hammerhead RNA (Figure 7). The high- 
affinity binding of different solution conformations of 
aminoglycosides is facilitated by the plasticity of the 
water-mediated contacts between the drug and the RNA. 
This model suggests a three-dimensional electrostatic 
complementarity (Figure 7), rather than highly specific 
contacts between the aminoglycoside and an RNA-recep- 
tor site and is in agreement with recent studies [l&33]. 
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Impact of the recognition model on drug design Figure 6 
The large body of biochemical and structural data avail- 
able for the hammerhead ribozyme allows the straightfor- 
ward assessment of hypotheses focusing on drug-RNA 
interactions. Measuring the inhibitory effects of drugs on 
the catalytic activity of the ribozyme provides an elegant 
way of monitoring their RNA-binding ability. Recent 
efforts in studying the hammerhead-aminoglycoside 
system have led to a recognition model based on structural 
electrostatic complementarity: aminoglycosides provide a 
three-dimensional framework in which combinations of 
positively charged ammonium groups are arranged to fit 
the negatively charged metal-ion-binding pockets created 
by the electrostatic field around the hammerhead RNA 
fold. The combined experimental and theoretical studies 
show that the inhibition potential of aminoglycosides is 
dependent on the following considerations: the number of 
charged ammonium groups in the aminoglycoside; the 
basicity of the amines; and the number of different, but 
energetically similar, solution conformers that can replace 
effectively several metal ions in the hammerhead RNA. 
Thus, synthetic organic chemistry, molecular biology and 
molecular modeling come together to yield an intriguing 
recognition model that provides new insights into the 
design of RNA-targeted drugs. 
W 
In what ways is the information gained from these studies 
relevant for explaining the recognition between small 
molecules and RNA and, ultimately, for designing new 
drugs? Firstly, the work shows that theoretical approaches 
are now sophisticated enough to allow the development of 
recognition models that may be useful as a basis for ratio- 
nal drug design. Secondly, the work stresses the role of 
three-dimensional electrostatics in drug-RNA interac- 
tions: it is the relative spatial positioning of charges that 
drives both recognition and binding. Thirdly, although the 
displacement of water molecules and ions has been recog- 
nized for some time as an important element in RNA 
binding, the model presented here suggests that this is not 
a purely stochastic and haphazard process. Indeed, ions 
occupy definite positions in an RNA fold and their simul- 
taneous displacement requires a molecular framework of 
positive charges with appropriate geometry. 
The proposed recognition model invokes straightforward 
strategies for drug design. To start with, the carbohydrate 
moieties of aminoglycosides constitute exquisite scaffolds 
around which positive charges, such as ammonium groups, 
can be organized. The interaction strength between the 
cationic groups and the RNA host can be modulated by 
electronegative neighboring substituents such as hydroxyl 
groups. Furthermore, the enormous versatility in forming 
glycosidic linkages between the carbohydrate moieties 
provides an adequate three-dimensional diversity for 
specifically targeting the various RNA pockets and folds 
encountered in potential biological targets. 
Molecular models of complexes obtained by docking solution 
conformations of aminoglycosides with the crystal structure of the 
hammerhead RNA (adapted form [36]). (a) Representative complex 
between neomycin B and the hammerhead. White spheres depict the 
position of magnesium ions in the crystal structure and green spheres 
show the ammonium groups in the aminoglycoside. The cleavage site 
is marked in yellow. (b) Interactions between aminoglycosides and the 
RNA in molecular-dynamics simulations of the docked complexes. 
cc) Interactions between magnesium ions and the RNA in molecular- 
dynamics simulations of the fully hydrated and neutralized hammerhead 
ribozyme. In (b) and (c), notice how water molecules (cyan) participate 
in the binding of the positively charged ions to the RNA. 
H3N+ 
Oh 
OH 
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Because of their importance for delineating the electrosta- 
tic environment of an RNA fold, electrostatic calculations 
and molecular simulations should be pursued and further 
developed [38]. Characterization of both the three-dimen- 
sional structure and the electrostatic environment of an 
RNA fold is a prerequisite for choosing the proper molecu- 
lar architecture and the positioning of charged groups in the 
design of a drug specific for a given RNA target. The 
promiscuous binding of aminoglycoside antibiotics to the 
hammerhead RNA arises from their conformational flexi- 
bility, which allows them to ‘remodel’ according to the 
RNA-binding surface. Although the ensuing entropic losses 
are compensated for by the simultaneous displacement of 
Figure 7 
Electrostatic complementarity between the electronegative cavity in 
the hammerhead RNA and the positively charged aminoglycosides. 
(a) Projection of the charge density on the molecular surfaces of a 
hammerhead-neomycin complex. Negatively charged surface patches 
are red, positively charged patches are blue. The positions of 
magnesium ions, as observed in the crystal structure of the 
hammerhead RNA, are indicated by light blue spheres. In the modelled 
complex, metal ions in the cavity are displaced by the aminoglycoside. 
(b) Field lines (yellow) illustrate the gradient of the electrostatic field 
1381 created by one aminoglycoside conformer. The positions of the 
displaced magnesium ions are shown as light blue spheres. The 
conformer and the orientation are the same as in (a) where the 
aminoglycoside is shown docked with the hammerhead RNA. Note the 
bundles of field lines emerging from positive surface patches of the 
aminoglycoside; they point in the directions of the positively charged 
metal ions that are located in the negatively charged binding pockets 
created by the RNA fold. The aminoglycoside adopts an orientation 
inside the cavity of the hammerhead so as to direct its positive charges 
into the metal-ion-binding sites of the RNA. This figure was made using 
the program GRASP [391. 
several ions and the rearrangement of water molecules at 
the interface, interactions with multiple partners is not 
desirable in drug design. Promising new directions include 
the design and synthesis of more rigid aminoglycosides and 
novel hybrid molecules that combine several different 
binding modes, such as ionic interactions and intercalation. 
Due to the complexity of the problem and the challenges it 
presents, we will have to rely on the ingenuity of chemists 
and molecular modelers for the design and synthesis of the 
next generation of specific RNA binders. 
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